Bone Anabolic Treatment in Patients With Chronic Kidney Disease: A Systematic Review
Basic & Clinical Pharmacology & Toxicology · 2026
DOI: 10.1111/bcpt.70293 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2026. Verfasst von Huriye Seyma Kafa und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Denmark. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Teriparatide, Bone Density Conservation Agents, Osteoporosis. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Augustinus Foundation, Augustinus Fonden.
Abstract (Originalsprache)
Background
Chronic kidney disease (CKD) associated osteoporosis leads to an increased risk of bone fracture in patients with CKD. Evidence on the efficacy and safety of anti‐osteoporotic medications is limited for this group. This systematic review aimed to examine the efficacy and safety of anabolic parathyroid hormone (PTH) treatment in patients with CKD Stages 4–5D.
Methods
MEDLINE, EMBASE and ClinicalTrials.gov were searched systematically for randomized controlled trials (RCTs) investigating teriparatide, natpara, or abaloparatide in adult patients with CKD Stages 4–5D, including kidney transplant recipients. The primary outcome was the change in bone mineral density (BMD) during follow‐up measured at the lumbar spine (LS), femoral neck (FN) and total hip (TH). The secondary outcomes included bone turnover markers, fractures, histomorphometric results from bone biopsies and adverse events (AEs).
Results
Two RCTs were included. A subgroup analysis of patients with CKD Stage 4 ( n = 5) showed that teriparatide improved BMD at the LS and FN. Another trial ( n = 61) in CKD Stage 5D showed significant BMD improvement at the TH compared to the control group. AEs were observed with higher frequency in the teriparatide‐treated group.
Conclusion
Treatment with teriparatide seems to improve BMD in patients with CKD Stages 4–5D, but evidence on efficacy and safety is limited. Trial Registration PROSPERO: CRD42024527086
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Huriye Seyma Kafa, Sabina Chaudhary Hauge
Förderung
- Augustinus Foundation
- Augustinus Fonden
Zitieren
APA
Kafa, H. S., Hauge, S. C., & Hansen, D. (2026). Bone Anabolic Treatment in Patients With Chronic Kidney Disease: A Systematic Review. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70293
Vancouver
Kafa HS, Hauge SC, Hansen D. Bone Anabolic Treatment in Patients With Chronic Kidney Disease: A Systematic Review. Basic & Clinical Pharmacology & Toxicology. 2026. doi:10.1111/bcpt.70293
BibTeX
@article{Kafa2026,
author = {Kafa, Huriye Seyma and Hauge, Sabina Chaudhary and Hansen, Ditte},
title = {Bone Anabolic Treatment in Patients With Chronic Kidney Disease: A Systematic Review},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2026},
doi = {10.1111/bcpt.70293}
}
EUVIMED